The syndicated ChartTrends: Multiple Sclerosis (US) report allows clients to better understand the actual treatment of multiple sclerosis (MS) with disease-modifying therapies (DMTs) through comparison of what physicians self-report about disease management to what occurs at the patient level. Through an in-depth review of charts from patients currently treated with Aubagio, Avonex, Betaseron, Copaxone, Gilenya, Rebif, Tecfidera, and Tysabri, details such as product initiation, switching, monitoring, and a host of tests and patient demographic variables help define patient types and identify drivers of therapy choice. The report also evaluates physician receptivity to products in development for the treatment of MS, and identifies potential characteristics of patient candidates for each product.

Questions Answered in This Report:

  • What are the demographics/treatment history of patients treated with DMTs, including diagnosis, MS symptoms, comorbidities, exacerbations, and disease progression? How are MRI and laboratory assessments used in the monitoring of MS patients?

  • What is the treatment paradigm for the chronic management of MS? What is the paradigm for the management of exacerbations and MS-related symptoms?

  • How frequently are patients tested with the anti-JC virus antibody assay? What factors drive the decision to test patients with the anti-JC virus antibody assay? How do test results impact prescribing behavior?

  • What factors drive the decision to initiate DMT treatment in treatment-naïve patients? What drives the selection of current DMT brands? What drives the discontinuation of therapy?

  • What is a typical patient profile for each of the individual DMT brands?

  • How receptive are physicians to products in development for MS? What are some identifying characteristics of potential candidates for these products?


Sample Methodology:

- ~200 fellowship-trained neurologists complete an online quantitative survey plus patient audits for between four to seven of their MS patients

To qualify, respondents must meet the following criteria:

- Minimum of 20 patients with relapsing-remitting MS under management

- Have been in practice a minimum of 2 years and a maximum of 35 years

- More than 75% of professional time spent in clinical practice

Each patient record meets the following criteria:

- At least 18 years of age

- Be treated with a DMT for at least the past six months


- Final report in PowerPoint format

- Complete set of frequency tables, summary statistics, and cross tabulations can be provided upon request

- Database containing de-identified patient audit data in SPSS and/or Excel available upon request

Physician Research:

- Neurologists


- United States

Key Drugs Covered:

- Aubagio (teriflunomide), Avonex (interferon-beta-1a intramuscular), Betaseron (interferon-beta-1b), Co-paxone (glatiramer acetate), Extavia (interferon-beta-1b), Gilenya (fingolimod), Rebif (interferon-beta-1a subcutaneous), Tecfidera (dimethyl fumarate), Tysabri (natalizumab), Lemtrada (alemtuzumab), Plegridy (pegylated interferon-beta-1a subcu-taneous), Nerventra (laquinimod), daclizumab, ocrelizumab

Key Companies Mentioned:

- AbbVie, Active Biotech, Bayer, Bio-gen Idec, EMD Serono (a Merck KGaA company), Genentech, Gen-zyme (a Sanofi company), Novartis, Pfizer, Roche, Teva

Related Reports:

TreatmentTrends®: Multiple Sclerosis (US) 2014

TreatmentTrends®: Multiple Sclerosis (EU) 2013

LaunchTrends®: Aubagio (US) 2013

LaunchTrends®: Tecfidera (US) 2014

LaunchTrends®: Lemtrada (US) TBD

DecisionBase®: Multiple Sclerosis-Relapsing Remitting 2014

DecisionBase®: Multiple Sclerosis-Chronic Progressive 2014

Pharmacor®: Multiple Sclerosis 2014

Treatment Algorithms®: Multiple Sclerosis 2014

Physician and Payer Forum®: Multiple Sclerosis (US) 2014

Physician and Payer Forum®: Multiple Sclerosis (EU) 2014

PatientBase®: Multiple Sclerosis in G7 2014

Related Reports

Multiple Sclerosis - Landscape & Forecast - Disease Landscape & Forecast

The maturing yet highly lucrative market for multiple sclerosis (MS) disease-modifying therapies (DMTs) will c...

View Details

Multiple Sclerosis | Disease Landscape and Forecast | G7 | 2020

The maturing yet highly lucrative market for multiple sclerosis (MS) disease-modifying therapies (DMTs) will continue to fragment as new entrants drive further shifts in a complicated treatment alg...

View Details

Multiple Sclerosis - Current Treatment - Detailed, Expanded Analysis (US)

Three disease-modifying therapies (DMTs)—EMD Serono’s Mavenclad, Novartis’s Mayzent, and Biogen’s Vumerity—joined the crowded U.S. multiple sclerosis (MS) market just...

View Details

Multiple Sclerosis - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis Multiple Sclerosis 2020 – Main Report Dashboard (US)

With more than a dozen immunomodulatory disease-modifying therapies (DMTs) available to treat multiple sclerosis (MS) and more in the pipeline, the treatment journey for U.S. MS patients continues...

View Details